Arcellx, Inc. $ACLX Shares Sold by Strs Ohio

Strs Ohio lessened its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX) by 21.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,869 shares of the company’s stock after selling 4,700 shares during the period. Strs Ohio’s holdings in Arcellx were worth $1,100,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. CWM LLC grew its holdings in shares of Arcellx by 267.0% during the third quarter. CWM LLC now owns 345 shares of the company’s stock valued at $28,000 after purchasing an additional 251 shares during the last quarter. Integrated Wealth Concepts LLC increased its position in Arcellx by 9.0% in the third quarter. Integrated Wealth Concepts LLC now owns 3,423 shares of the company’s stock worth $281,000 after buying an additional 283 shares during the period. MAI Capital Management bought a new stake in Arcellx in the third quarter valued at $26,000. Vanguard Personalized Indexing Management LLC lifted its position in Arcellx by 11.0% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 3,805 shares of the company’s stock valued at $312,000 after purchasing an additional 377 shares during the last quarter. Finally, State of Wyoming bought a new position in Arcellx in the 2nd quarter worth about $28,000. Institutional investors and hedge funds own 96.03% of the company’s stock.

Arcellx Price Performance

Arcellx stock opened at $115.07 on Thursday. Arcellx, Inc. has a 12-month low of $47.86 and a 12-month high of $115.13. The stock has a market capitalization of $6.73 billion, a PE ratio of -28.27 and a beta of 0.25. The firm has a 50 day simple moving average of $114.64 and a 200-day simple moving average of $88.40.

Arcellx (NASDAQ:ACLX) last announced its earnings results on Thursday, February 26th. The company reported ($1.01) EPS for the quarter, hitting the consensus estimate of ($1.01). The firm had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $13.40 million. Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%. On average, analysts forecast that Arcellx, Inc. will post -2.91 earnings per share for the current fiscal year.

Insider Activity at Arcellx

In other news, insider Rami Elghandour sold 89,916 shares of the business’s stock in a transaction on Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the sale, the insider owned 276,051 shares of the company’s stock, valued at approximately $31,447,729.92. The trade was a 24.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.35% of the company’s stock.

Analyst Upgrades and Downgrades

ACLX has been the topic of a number of recent analyst reports. Canaccord Genuity Group set a $115.00 price target on Arcellx in a report on Monday, February 23rd. UBS Group cut Arcellx from a “buy” rating to a “neutral” rating and raised their target price for the company from $100.00 to $115.00 in a research report on Tuesday, February 24th. Guggenheim downgraded Arcellx from a “buy” rating to a “neutral” rating and cut their target price for the company from $120.00 to $115.00 in a research note on Wednesday, February 25th. Robert W. Baird reiterated a “neutral” rating and set a $115.00 price target (up from $106.00) on shares of Arcellx in a research report on Monday, February 23rd. Finally, William Blair lowered Arcellx from a “strong-buy” rating to a “hold” rating in a report on Monday, February 23rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $111.87.

Arcellx Company Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.